Researchers at Mount Sinai Health System in New York have identified a gene with the potential to re-activate the heart’s own capacity for repair — a discovery that could change cardiac care globally.
Known as CCNA2 (Cyclin A2), this gene is actively involved during fetal heart development, enabling heart cells to proliferate. But after birth, it typically becomes dormant, which leaves adult hearts unable to regenerate when injured.
By using a safe viral vector to re-introduce CCNA2 into damaged human heart tissue, the researchers found that new, functioning heart cells could form — even in tissue from donors aged 21, 41 and 55. These newly formed cells showed normal contraction ability, pointing to a promising regenerative therapy.
Heart disease remains the world’s leading cause of death, with many patients receiving treatments focused on symptom-management rather than true tissue repair.
If CCNA2-based gene therapy can transition from lab research to clinical use, it may enable hearts to heal themselves without relying solely on mechanical devices or transplants. This could reduce hospital stays, improve quality of life, and dramatically enhance long-term outcomes.
During fetal development, CCNA2 is highly active, enabling cardiac cells to multiply and form a functioning organ. After birth, however, this activity drops off—leaving adult hearts without the same regenerative capacity.
The Mount Sinai team inserted the gene into injured heart tissue via a harmless viral delivery system. The result: regeneration of new heart muscle cells in human tissue samples, challenging the long-held belief that adult human hearts cannot repair themselves.
The findings mark a milestone in cardiac regenerative medicine, a domain that has seen nearly two decades of intensive research.
Lead researcher Hina Chaudhry, director of cardiovascular regenerative medicine at Mount Sinai, stated that the discovery “challenges the long-standing belief that adult heart cells cannot regenerate.” With the right intervention, she explains, “the heart can repair itself.”
If regulatory agencies such as the U.S. Food & Drug Administration (FDA) approve trials for CCNA2 gene therapy, we could witness a profound shift in how heart attacks and chronic heart failure are treated. Instead of only managing damage, therapies could aim to reverse it.
What This Means for Patients
- A future in which damaged hearts regenerate rather than simply surviving.
- Potentially fewer heart transplants or mechanical assist devices.
- Faster recovery after heart injury and improved long-term health outcomes.
- A new paradigm for treating cardiac conditions at their root, instead of solely addressing symptoms.
This breakthrough, focusing on the CCNA2 gene’s ability to trigger heart cell regeneration, opens the door to a future where hearts heal themselves — and millions of lives may benefit.